Post-transplant lymphoproliferative disorders (PTLD) are morphologically/clinically heterogeneous. The main goal of this study was to define the histogenesis of PTLD (B-cell phenotype, EBV-related) in seven pediatric patients after allogeneic T-cell-depleted bone marrow transplantation. Immunohistochemical stains using histogenetic markers, including Bcl-6 (expressed by germinal center (GC) B cells), MUM1/IFR4 (late GC and post GC B cells), and CD138 (post GC B cells), were performed on paraffin-embedded tissue. By morphology, four cases were classified as polymorphic PTLD and three as monomorphic PTLD, according to the WHO classification. By the expression pattern of histogenetic markers, five cases (two polymorphic, three monomorphic PTLD) were of late GC/early post GC B-cell origin expressing only MUM1/IRF4. The remaining two cases (one monomorphic, one polymorphic PTLD) were of post GC Bcell origin expressing MUM1/IRF4 and CD138, but not Bcl-6. Our study indicates that histogenesis of PTLD may be defined by histogenetic markers using immunohistochemistry. The results suggest that most pediatric PTLD are of late GC/early post GC B-cell origin, and a minor group is of post GC B-cell origin. The histogenesis of PTLD appears independent of morphologic appearance. Further studies are warranted to confirm our observation and to evaluate the clinical significance of histogenetic pattern of PTLD.
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PTLD after transplantation occurs more frequently in children than in adults, and is a significant challenge in clinical management. 3 The higher frequency of PTLD in children may likely be due to the fact that children are more often EBV seronegative at the time of transplantation. [3] [4] [5] Additionally, recent studies have shown that a rising EBV viral load after transplantation correlates with the risk of developing PTLD in pediatric population. 6, 7 In the setting of allogeneic stem cell transplantation, the patients receiving T-cell-depleted mismatched bone marrow transplant have the highest risk of developing PTLD at the rate of 6-9%. [8] [9] [10] [11] Most cases of PTLD occur within 3 months after transplant. [8] [9] [10] [11] [12] The clinical presentation of PTLD comprises a spectrum from localized/subclinical to widely disseminated/symptomatic disease. 11 PTLD may cause demise quickly after the onset of signs and symptoms, through massive organ infiltration or associated dysfunction. Mortality rates reported for children who develop PTLD are high, and range from 36 to 69%. 3, 4 Our understanding of B-cell lymphoma histogenesis has progressed rapidly due to the availability of well-defined histogenetics markers, including Bcl-6, MUM1/IRF4 (multiple myeloma-1/interferon regulatory factor-4), and CD138. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Studies have shown that expression of Bcl-6 occurs immediately after B cells enter the germinal center (GC), and is maintained until these cells exit the GC. MUM1/IRF4 expression begins only at the centrocyte (late GC B cells) stage. This suggests that MUM1/IRF4 expression by GC B cells occurs in a final step of B-cell differentiation in the GC. When B cells exit the GC, they maintain their MUM1/IRF4 expression. Then, in an additional step toward differentiation into plasma cells/ memory cells, they acquire the expression of CD138. CD138 (a member of the syndecans family of integral membrane proteoglycans) expression has been shown to play a key role in plasma cell differentiation. [13] [14] [15] [16] [17] [18] [19] Carbone et al 23 recently reported that the AIDS related B-cell lymphomas could be classified into three histogenetic subgroups (GC, late GC/early post GC or post GC origin) based on the expression pattern of Bcl-6, MUM1/IRF4, and CD138. The neoplastic cells of GC origin express only Bcl-6, those of late GC/early post GC origin express MUM1/IRF4 but not Bcl-6 or CD138, and those of post GC origin express MUM1/IRF4 and CD138 but not Bcl-6. Furthermore, their results suggest that the histogenesis of AIDS-related B-cell lymphomas correlates with the clinical presentation.
Although the histogenesis of B-lymphocytes may provide important insights into the pathogenesis and clinical course of PTLD, this has not been well defined, especially in children. The main goal of the current study was to determine if the histogenesis of PTLD occurring in children could be determined by the expression pattern of Bcl-6, MUM1/IRF4, and CD138. Furthermore, we evaluated if the histogenesis pattern correlated with the current WHO morphologic classification scheme or clinical presentation of the cases studied.
Materials and methods

Patients
Seven cases of pediatrics B-cell (CD20 þ ) PTLD, EBV related, that developed after allogeneic T-cell-depleted bone marrow transplantation were studied retrospectively. Patients were retrieved from the files of the Department of Pediatric Pathology, Children' 
Immunohistochemical stains
Immunohistochemical stains were performed on formalinfixed paraffin-embedded tissues from these cases. Paraffin sections were mounted on Fisherbrand/Plus Superfrost Precleaned slides, heated at 601C for 30 min, deparaffinized, and rehydrated. The stains for EBV-LMP (late membrane protein), CD20 and histogenetic markers, including Bcl-6, MUM1/IRF4, and CD138, were performed with the antigen-retrieval techniques, as described in Table 2 . The CD20 (L-26) stain was performed in the consecutive section to help in evaluating the expression of the histogenetic markers in B cells (CD20 þ ). Nonspecific protein-binding sites were blocked by serum for 5 min and the primary antibody added at different dilutions ( Table 2 ). All slides were stained using the DAKO automated immunostainer (DAKO, Carpinteria, CA, USA). The slides were incubated for 15 min in labeled streptavidin-biotin (LSAB) for linking, and subsequently labeled with diaminobenzidine (DAB) chromogen. Appropriate positive and negative controls were used in all cases. 
Real-time quantitative PCR for EBV viral load
Three cases had EBV viral load monitoring performed after bone marrow transplantation and over the course of PTLD. EBV viral load was determined by real-time quantitative PCR with Taqman probe (manuscript in preparation, Orentas et al) using primers specific for the EBER-1 region of the viral genome.
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Interpretation of the expression of histogenetic markers
Expression of Bcl-6, MUM1/IRF4, and CD138 was systematically reviewed by two of the authors (CC and NA). Percentages of B cells, highlighted by the CD20 stain in the consecutive section, expressing Bcl-6, MUM1/IRF4, and CD138, were counted and recorded. The expression of each marker was defined as follows: negative, o20% of B cells expressing each marker, since small amounts of residual normal B cells may express these markers; 21, 22 þ , 20-50% of B cells expressing each marker; þ þ , 51-80% of B cells expressing each marker; and þ þ þ , 480% of B cells expressing each marker. The expression of CD138 and MUM1/IRF4 in mature plasma cells was not counted because the expression of these two markers was normally acquired during the differentiation toward plasma cells.
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Results
All patients received the similar conditioning regimen including cyclophosphamide, cytosine arabinoside, and total body irradiation ( Table 1 ). All allografts were 1.5-2 logs T-cell depleted by monoclonal antibody (OKT3 or T10B9), as described in previous reports. 25, 26 Post-transplant immune suppression was with cyclosporin A. These seven patients represented 2.25% of 311 children who underwent T-cell-depleted allogeneic bone marrow transplant during the period of this study.
The patients developed PTLD within 47-98 days after bone marrow transplant (Table 3) . At the time of diagnosis of PTLD, only one patient (case #1) showed involvement of multiple sites including lung, liver, and ear. The remaining six patients presented with localized disease (Table 3) . Five patients were treated with decreased/discontinued cyclosporin A, one patient (case #1) with Rituximab and donor T-cell infusion, and one patient (case #6) with Rituximab and ganciclovir. The majority of patients responded well to local treatment and decreased/discontinued immunosuppressive treatment without systemic therapy. Only two patients (case #1 and #2) had clinically progressive disease and died from PTLD (confirmed by autopsy in case #1). In the remaining five patients, PTLD was considered cured clinically (confirmed by autopsy in case #4 and #6).
Review of the morphology revealed that four cases were polymorphic PTLD according to the WHO classification (Table 3) . These cases showed destructive lymphocytic infiltrates composed of small-to intermediate-sized lymphocytes, large transformed lymphocytes, immunoblasts, and plasma cells (Figure 1a , case #7). The remaining three cases were monomorphic PTLD, diffuse large B-cell lymphoma, one centroblastic variant, and two immunoblastic variants (Table 3) . These cases showed monotonous proliferation of large atypical lymphocytes with morphologic characteristics of either centroblasts or immunoblasts (Figure 1b, case #5) . Areas of necrosis were present in all cases.
Histogenetic studies showed that five of the seven PTLD lesions were late GC/early post GC origin, and the remaining two were post GC origin ( Table 3 ). The former group expressed MUM1/IRF4 but not Bcl-6 or CD138, while the latter expressed MUM1/IRF4 and CD138 but not Bcl-6. In polymorphic PTLD, the expression of these markers was homogenous among the small-to intermediate-sized lymphocytes and large transformed B lymphocytes (Figure 1c, d, case #7 ). The expression of MUM1/ IRF4 was demonstrated as nuclear (strong)/cytoplasmic (weak) staining (Figure 1c) , and the CD138 as membrane (strong)/cytoplasmic (weak) staining (Figure 1d ). There was no case arising from GC B -cell, since none of the cases showed Bcl-6 expression in more than 20% of B lymphocytes.
The histogenesis of B lymphocytes in the PTLD lesions did not correlate with the morphologic classification of PTLD by the WHO classification. Two of five cases of late GC/early post GC B-cell origin (expressing only MUM1/ IRF4) were monomorphic PTLD, while the remaining three were polymorphic PTLD. Similarly, one of the two cases of post GC B-cell origin (expressing both MUM1/ IRF4 and CD138) was monomorphic PTLD and the other was polymorphic PTLD.
Although the number of cases was small, PTLD of post GC B-cell origin appeared more likely to involve lymph nodes than PTLD of late GC/early post GC B-cell origin (2/2 vs 0/5, Po0.05, Fisher's exact, Table 3 ). Two (case #1 and #2) of five patients with PTLD of late GC/early post GC B-cell origin had progressive disease and PTLD significantly contributed to their death, while both patients of post GC B-cell origin were cured without evidence of PTLD (Table 3) . EBV viral load monitoring by real-time PCR assay was performed on three patients, and in all cases showed a strong correlation between elevated viral loads and development of PTLD. Additionally, a decreasing viral load was associated with improvement of PTLD in two of three cases (case #4 and #6). The results of a representative patient (case #4) are shown in Figure 2 .
Discussion
Using a combination of several histogenetic markers, namely Bcl-6, MUM1/IRF4, and CD138, we have shown that pediatric PTLD of B-cell lineage can be classified into two histogenetic groups. The major group is of late GC/ early post GC origin expressing MUM1/IRF4 but not Bcl-6 or CD138, while the minor group is of post GC origin expressing MUM1/IRF4 and CD138 but not Bcl-6. Additionally, our results suggest that the association between the histogenesis of B cells in pediatric PTLD and clinical course of children with PTLD warrants further evaluation. 
PTLD histogeneisis
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Our results indicate that the histogenesis of PTLD is comparable to that of lymphoma arising in the context of human immunodeficiency virus (HIV) infection. This is not surprising since both entities are associated with immunosuppression/immunodeficiency. Carbone et al have recently reported that expression of Bcl-6, MUM1/IRF4, and CD138 segregates into three major histogenetic patterns among HIV-associated lymphomas: (1) the Bcl-6 þ /MUM1/IRF4À/CD138À pattern, (2) the Bcl-6À/ MUM1/IRF4 þ /CD138À pattern, and (3) the Bcl-6À/ MUM1/IRF4 þ /CD138 þ pattern, corresponding to GC, late GC/early post GC or post GC B-cell origin, respectively. 23 The last two patterns were also observed in the PTLD cases in the current study. We did not identify any case expressing Bcl-6, because the vast majority of our cases expressed EBV-LMP. Mutual exclusion of EBV-LMP and Bcl-6 expression has been well acknowledged in HIV/ AIDS-associated lymphomas. 23, 27 Our results suggest that this mutual exclusion expression pattern is also present in PTLD. Furthermore, our findings partially agree with a recent study by Paessler et al. 28 They reported that B-cell PTLD could be divided into two broad categories corresponding to the early (CD10À/BCL-6À/SHP-1 þ / CD138À) and late (CD10À/BCL-6À/SHP-1 þ /CD138 þ ) post GC B-cell origin. 28 It would be of great interest to study the MUM1/IRF4 expression in the former group, to see if any of these cases may be of late GC/early post GC origin, as shown in the current study.
We did not observe any correlation between the histogenesis of PTLD and the morphologic classification of PTLD. Thus, the determination of histogenesis requires immunohistochemistry using the histogenetic markers. It should be emphasized that the antibodies selected in this study are commercially available, and have been commonly used in clinical laboratories. Furthermore, we observed that the expression of these markers was homogenous among the small-to medium-sized and large B lymphocytes in polymorphic PTLD lesions. Thus, although the B lymphocytes in these lesions are morphologically heterogenous, our observation suggests that these cells may have developed from the same histogenetic origin.
Although the current study is limited by a small sample size, the histogenesis of PTLD appears to be correlated with the clinical presentation in our patients. The patients with PTLD of post GC origin were more likely to involve lymph nodes than those with PTLD of late GC/early post GC origin. Additionally, the patients with PTLD of late GC/early post GC origin seem to have a more aggressive clinical course than those with PTLD of post GC origin. Two patients of the former group had progressive disease, which was not present in the latter group. It is well known that patients with PTLD have heterogenous clinical courses.
11 Some patients respond to reduced immunosuppression without systemic therapy, while others have rapidly progressive disease despite intensive treatments. Currently, there is no reliable marker to predict the clinical course of PTLD. Neither morphologic classification nor evaluation of monoclonality has proven capable of reliably predicting disease behavior. 2 Further studies are warranted to determine if the histogenetic pattern of PTLD has prognostic significance.
Improvement of PTLD concurred with the declining EBV viral load in two of three patients in this study (case #4 and #6). The correlation between EBV infection and development of PTLD in children has been well documented. Recently, this correlation has been further strengthened by demonstrating the increasing levels of EBV viral load after bone marrow transplant correlating with the development of PTLD using quantitative PCR. 6, 29 The results of the EBV viral load determined by real-time quantitative PCR in the current study agree with the previous studies. Although Yang et al 30 have published that a decline in viral load may not correlate with resolution of PTLD, the prevalence of this finding is not yet established. Our observation demonstrates that, in two of three cases, a resolution of high viral load in the blood does correlate with resolution of PTLD. Thus, monitoring of EBV viral load by real-time quantitative PCR may have a role in determining patients' response to treatment in addition to predicting the occurrence of PTLD. This is important since disease that requires more aggressive therapy and disease that responds to decrease in immunosuppression and/or rituximab can better be distinguished. There were several important clinical differences between our patients and those in previous reports (Table 4) . 7, 9, 10, [31] [32] [33] [34] [35] [36] First, the majority of our patients were diagnosed at the stage of localized disease. In contrast, most previously reported pediatric PTLD cases presented with disseminated disease (Table 4) . Furthermore, all our cases were diagnosed before the death of patients, while about half of patients were diagnosed at the time of autopsy in the previous studies. Second, only two of our seven patients had progressive PTLD. By contrast, the vast majority of patients died of PTLD in previous reports. The improvement of outcome may partially result from the accurate diagnosis of PTLD at an early stage without dissemination of disease.
In summary, our results indicate that most pediatric PTLD occurring after bone marrow transplant are derived from late GC/early post GC B cells, and a minor group is derived from post GC B cells. The histogenesis of PTLD appears independent of morphologic appearance. Further studies with a larger sample size are warranted to confirm our observation and to evaluate the prognostic significance of histogenetic pattern of PTLD. 
